Plan-les-Ouates (Switzerland), October 28, 2011 – Viroblock S.A., a company with a
highly innovative, broadly applicable anti-viral air filtration technology, initially focused
on development and commercialization of anti-viral face-masks, today announced the
successful closure of a 3.3 million CHF Series C financing round.
Dr Jamie Paterson, CEO of Viroblock, said “these funds allow Viroblock to complete
the development of our anti-viral face-mask and start its commercialization in 2012.”
Unlike other face-masks, the Viroblock mask can kill enveloped viruses, such as
H1N1, H5N1 and SARS, on pass through air.
The financing round was led by Dr Peter Pfister and Dr Erich Platzer from the
StartAngels Network, with strong support from new and existing investors. Dr Platzer
noted that “pathogenic respiratory viruses are an increasing concern both for
professional health workers and the general public. We are therefore excited to invest
in Viroblock's unique solution to this everyday problem.”
Viroblock S.A. is a Swiss-based company focused on developing a novel anti-viral
technology that is both rapid acting and broad spectrum. Applied to non-woven fabric,
the technology is particularly suited for air filtration products. In fact, previous work
has shown Viroblock fabric to kill over 99% of H5N1 viruses when challenged in
standardized aerobiology experiments.
Viroblock is currently scaling up the production of its anti-viral technology and
expects to enter the market with an anti-viral mask in 2012.
For further information please contact
Jamie Paterson, CEO Viroblock S.A.
+41 79 831 60 06
18, chemin des Aulx
CH-1228 Plan-les-Ouates, Geneva, Switzerland